AbbVie has received United States Food and Drug Administration approval for Skyrizi, or risankizumab-rzaa, in children aged six years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as those with active psoriatic arthritis. The expanded label introduces a 55 mg prefilled syringe for patients weighing less than 40 kg, while children weighing 40 kg or more receive the existing 150 mg formulation.
Why the new 55 mg Skyrizi syringe makes this more than a routine age extension
The new presentation addresses one of the less visible barriers to extending adult biologics into younger populations. A medicine may have an established mechanism and extensive adult safety experience, but pediatric use also requires an appropriate exposure range, practical injection volume and delivery format for children with substantially lower body weight.
Children weighing less than 40 kg will receive 55 mg at week zero, week four and every 12 weeks thereafter. Those weighing at least 40 kg will receive 150 mg on the same schedule. That creates a relatively simple weight threshold and preserves the maintenance interval that has helped differentiate Skyrizi in adult dermatology and rheumatology.
The practical value extends beyond pharmacokinetics. Children aged six to under ten are expected to have the injection administered by an adult, while administration for older pediatric patients should occur by or under adult supervision. A ready-to-use prefilled syringe can reduce the need for dose preparation and may make treatment more manageable across specialist clinics, specialty pharmacies and households.
However, a pediatric formulation does not automatically solve access. Clinics will need to manage two strengths, insurers will need to update authorization policies, and families may face treatment delays if pharmacy systems or payer formularies do not immediately recognise the new dose. Children approaching the 40 kg threshold will also require accurate weight monitoring to determine when a switch to the 150 mg presentation is appropriate.
How convincing is the OptIMMize evidence supporting pediatric plaque psoriasis use?
The plaque psoriasis approval rests on a four-part Phase 3 program involving 137 pediatric participants aged six years and older. The development plan included two pharmacokinetic lead-in cohorts, a randomized and assessor-blinded active-controlled cohort in adolescents, and a single-arm open-label cohort in younger children.
The randomized cohort enrolled 82 participants aged 12 years and older. They were allocated in a two-to-one ratio to Skyrizi or ustekinumab, providing an active comparator rather than relying only on historical expectations or an untreated control. The co-primary efficacy measures evaluated the proportion achieving clear or almost-clear skin on the static Physician’s Global Assessment, together with a meaningful improvement from baseline, and the proportion reaching at least a 75% improvement in the Psoriasis Area and Severity Index at week 16.
Among the 54 adolescents assigned to Skyrizi, 69% achieved clear or almost-clear skin, 85% reached PASI 75, 65% reached PASI 90 and 41% achieved complete skin clearance at week 16. These results indicate activity across progressively demanding clearance thresholds rather than improvement on a single measure.
The withdrawal phase adds evidence that continuing therapy contributed to maintaining disease control. Among initial responders who were subsequently reassigned, 95% of those continuing Skyrizi retained the specified clear or almost-clear response at week 52, compared with 39% of those withdrawn from treatment.
That result supports the durability of scheduled maintenance, but the small responder groups require caution. The week 52 comparison involved 19 patients continuing treatment and 18 undergoing withdrawal, leaving the percentages sensitive to changes in only a few participants.
The evidence is also less rigorous in the youngest age group. Thirty children aged six to under 12 were enrolled in a single-arm open-label cohort, meaning there was no concurrent comparator and both investigators and participants knew which treatment was administered. Pharmacokinetic matching and consistency across age groups can support regulatory confidence, but they cannot fully replace a large controlled efficacy trial in younger children.
The active comparator in the adolescent cohort improves the clinical relevance of the program, although the publicly available prescribing information does not establish that Skyrizi is superior to ustekinumab. The data therefore support efficacy and maintenance without resolving which biologic should be preferred across every pediatric profile.
Why the psoriatic arthritis approval carries a different evidentiary profile
The active psoriatic arthritis indication is the more analytically important part of the approval because it was not supported by a dedicated randomized pediatric arthritis efficacy study. Instead, the regulatory case combined results from well-controlled adult psoriatic arthritis trials with pharmacokinetic information from adults and pediatric psoriasis patients, plus pediatric safety and immunogenicity evidence.
Population pharmacokinetic modelling predicted that the recommended weight-based doses would produce exposures in pediatric patients comparable to those observed in adults with psoriatic arthritis. This extrapolation approach can reduce the need to run difficult trials in a relatively small pediatric population, particularly when disease biology, treatment response and drug exposure can be reasonably linked across age groups.
The limitation is that comparable drug exposure is not the same as direct evidence of comparable joint outcomes. The pediatric psoriasis program measured skin clearance rather than swollen joints, tender joints, enthesitis, dactylitis, physical function or other arthritis-specific endpoints. Adult trials established that risankizumab can improve those manifestations, but clinicians adopting the pediatric label will initially have less direct evidence about how children with different patterns of joint disease respond.
This distinction is unlikely to prevent use, since extrapolation has supported other pediatric rheumatology labels. It does mean that post-approval evidence will carry unusual importance. Treatment persistence, control of joint inflammation, mobility, functional outcomes and the frequency of switching will help determine whether predicted exposure translates into consistent real-world arthritis benefits.
How does Skyrizi alter competition across pediatric psoriasis and psoriatic arthritis?
Skyrizi does not enter an empty treatment market. Pediatric specialists already have biologics targeting tumour necrosis factor, interleukin-17 and the shared interleukin-12 and interleukin-23 pathway. Several established medicines also cover both pediatric psoriasis and juvenile psoriatic arthritis, while others have an indication for only one side of the disease spectrum.
The differentiation is mechanistic and operational. Skyrizi selectively targets the p19 subunit of interleukin-23 and is the first selective IL-23 inhibitor approved in the United States for patients aged six years and older weighing less than 40 kg across plaque psoriasis and psoriatic arthritis. Its every-12-week maintenance schedule after the first two doses may also appeal where reducing injection frequency is a meaningful consideration.
However, prescribing decisions will not be made on injection frequency alone. Specialists will consider disease severity, whether skin or joint manifestations dominate, previous treatment exposure, comorbid inflammatory conditions, infection history, family preference and familiarity with each therapeutic class. Some competing products have longer pediatric use histories or labels extending to younger children with arthritis.
Payers may also view the new label through a cost-management lens rather than a mechanism-first lens. Prior authorization, step therapy and preferred-product arrangements can direct patients toward older biologics or lower-cost alternatives before approving a newer IL-23 therapy. Ustekinumab and its expanding biosimilar market may create a particularly relevant pricing comparison because it already has pediatric psoriasis and psoriatic arthritis indications.
Skyrizi could still gain traction when clinicians seek selective IL-23 inhibition, a quarterly maintenance schedule or one treatment that can address both skin and joint disease. The breadth of the label makes the medicine easier to position across dermatology and rheumatology, but comparative effectiveness and payer policy will determine whether that positioning converts into widespread first-line biologic use.
What safety and implementation questions remain after the pediatric approval?
The pediatric plaque psoriasis safety database included 137 participants treated for up to 52 weeks, with the observed profile described as consistent with the established adult psoriasis experience. The most common adverse reactions associated with Skyrizi in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection-site reactions and fungal skin infections.
The prescribing framework also retains warnings related to serious hypersensitivity reactions and infections. Patients are evaluated for tuberculosis before treatment, and age-appropriate vaccinations are expected to be completed under current immunisation guidance. Live vaccines are avoided around treatment because the medicine alters immune activity.
Consistency with adult safety is reassuring, but the total pediatric exposure remains modest when compared with the thousands of adults included across the Skyrizi development program. Rare events, age-specific immune effects or patterns that emerge only after several years may not be visible in a one-year dataset of this size.
Long-term follow-up will therefore matter. The OptIMMize extension program is designed to collect several years of safety, tolerability and efficacy information from participants continuing risankizumab. Observers will watch for serious infections, hypersensitivity, treatment discontinuation, immunogenicity and any unexpected effects during growth and adolescence.
Implementation will also depend on coordination between dermatologists, rheumatologists, paediatricians, pharmacies and insurers. A child presenting mainly with skin disease may begin in dermatology, while joint symptoms can require rheumatology involvement and additional monitoring. A label covering both conditions reduces one barrier, but it does not eliminate the need for multidisciplinary disease assessment.
What does the pediatric label mean for AbbVie’s wider immunology strategy?
For AbbVie, the approval extends a flagship immunology asset into a younger population and gives the Skyrizi franchise another layer of lifecycle expansion. The immediate pediatric commercial opportunity is smaller than the adult market, but the strategic value is broader than the number of eligible children.
The expanded label increases familiarity with Skyrizi among pediatric dermatologists and rheumatologists, creates a new entry point for patients who may require long-term disease control, and strengthens the product’s position across multiple stages of immune-mediated disease. It also demonstrates AbbVie’s willingness to invest in pharmacokinetic studies, pediatric formulations and long-duration follow-up rather than depending solely on the adult presentation.
The United States decision arrived shortly after European approval for pediatric moderate-to-severe plaque psoriasis. The American label is broader because it also covers active psoriatic arthritis, giving AbbVie a differentiated message across skin and joint disease.
That advantage should not be overstated. Pediatric prescribing grows gradually, specialists tend to value long-term experience, and reimbursement can lag behind regulatory approval. The commercial effect will depend less on an immediate surge in demand and more on whether Skyrizi earns a durable place within treatment pathways over several years.
What will clinicians, regulators and industry observers watch after launch?
The first question will be how frequently the new 55 mg syringe is prescribed and whether access systems can accommodate the formulation without avoidable delays. Uptake among children under 40 kg will provide an early indication of whether the product presentation addresses a genuine treatment gap or remains restricted by payer requirements.
The second question concerns the pediatric psoriatic arthritis indication. Real-world joint outcomes will be closely examined because the approval relies on extrapolation and exposure modelling rather than a dedicated pediatric arthritis efficacy trial. Registries and post-marketing studies could provide evidence on mobility, disease activity, treatment persistence and switching that is not available at approval.
The third question is competitive positioning. Skyrizi offers selective IL-23 inhibition, weight-based dosing and a relatively infrequent maintenance schedule, but it must compete with therapies that have established pediatric experience, broader age coverage or favourable payer placement.
The FDA decision meaningfully expands the pediatric treatment landscape, particularly for smaller children who can now receive a purpose-built 55 mg presentation. Its longer-term significance will be determined by whether the strong skin responses seen in the clinical program are sustained in routine care, whether modelled arthritis efficacy is confirmed in practice, and whether families can obtain the treatment without access becoming the toughest endpoint of all.
FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →